An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Acronyms ORKIDS
- Sponsors Melinta Therapeutics; The Medicines Company
- 09 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 09 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2020.
- 07 Oct 2018 Results presented at the IDWeek 2018